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A B S T R A C T
The FMR1 premutation confers a 40–60% risk for males of developing a neurodegenerative disease called the
Fragile X-associated Tremor Ataxia Syndrome (FXTAS). FXTAS is a late-onset disease that primarily involves
progressive symptoms of tremor and ataxia, as well as cognitive decline that can develop into dementia in some
patients. At present, it is not clear whether changes to brain function are detectable in motor regions prior to the
onset of frank symptomatology. The present study therefore aimed to utilize an fMRI motor task for the ﬁrst time
in an asymptomatic premutation population.
Premutation carriers without a diagnosis of FXTAS (n= 17) and a group of healthy male controls (n= 17),
with an age range of 24–68 years old, were recruited for this cross-sectional study. This study utilized neuroi-
maging, molecular and clinical measurements, employing an fMRI ﬁnger-tapping task with a block design
consisting of sequential ﬁnger-tapping, random ﬁnger-tapping and rest conditions. The imaging analysis con-
trasted the sequential and random conditions to investigate activation changes in response to a change in task
demand. Additionally, measurements were obtained of participant tremor, co-ordination and balance using the
CATSYS-2000 system and measures of FMR1 mRNA were quantiﬁed from peripheral blood samples using
quantitative real-time PCR methodology.
Premutation carriers demonstrated signiﬁcantly less cerebellar activation than controls during sequential
versus random ﬁnger tapping (FWEcorr < 0.001). In addition, there was a signiﬁcant age by group interaction in
the hippocampus, inferior parietal cortex and temporal cortex originating from a more negative relationship
between brain activation and age in the carrier group compared to the controls (FWEcorr < 0.001).
Here, we present for the ﬁrst time functional imaging-based evidence for early movement-related neurode-
generation in Fragile X premutation carriers. These changes pre-exist the diagnosis of FXTAS and are greatest in
older carriers suggesting that they may be indicative of FXTAS vulnerability.
1. Introduction
It is estimated that approximately 1 in 250–810 males in the general
population carry the FMR1 premutation; a genetic status conferred by
an expansion of the 5′ untranslated CGG repeat region of the FMR1 gene
from< 55 repeats to between 55 and 200 repeats (Rifé et al., 2003;
Sorensen et al., 2013). Up to 45 repeats is considered to be within the
normal range and 45–55 repeats is considered to be an intermediate
expansion. CGG repeat regions exceeding 200 usually become methy-
lated, and as such prevents transcriptional regulation, silencing the
FMR1 gene. This is known as a full mutation, causing Fragile X Syn-
drome, which is functionally and pathologically separate from disorders
linked to the Fragile X premutation (Tassone and Berry-Kravis, 2010).
Until relatively recently it was believed that carriers of the FMR1
repeat expansion were phenotypically unaﬀected. However, research
carried out over the last two decades has revealed that carriers of the
FMR1 premutation are at risk of developing a late onset neurological
condition called Fragile X-associated Tremor Ataxia Syndrome
(FXTAS), which is characterised by progressive core symptoms of
tremor, ataxia and cognitive decline. Males have a 40–60% chance of
developing FXTAS, whereas females are at lower risk, with a 8–16%
chance of developing the disease (Jacquemont et al., 2004; Hall et al.,
2005). The clinical presentation of FXTAS usually begins with subtle
cognitive decline, especially in executive function and working
memory, which develops into full dementia in about 40% of male pa-
tients (Bourgeois et al., 2007). Motor symptoms usually include tremor,
ataxia and inability for tandem gait. Parkinsonism can also occur in
some individuals with FXTAS, as well as peripheral neuropathy,
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autonomic dysfunction and endocrine dysfunction (Loesch et al., 2005;
Berry-Kravis et al., 2007; Wang et al., 2013). In addition to these
neurological symptoms, a diagnosis of FXTAS requires one or more
radiological ﬁndings (Hall et al., 2016), including global brain atrophy,
increased T2 signal intensity at the middle cerebellar peduncles (known
as the MCP sign) and thinning of the corpus callosum (Filley et al.,
2015; Brunberg et al., 2002). Evidence suggests that the pathology of
FXTAS may be driven primarily by a two to eight fold increase in FMR1
mRNA (Li and Jin, 2012; Garcia-Arocena and Hagerman, 2010). In-
tranuclear inclusions in multiple brain cell types are a pathological
hallmark of FXTAS, and in both FXTAS models and patient brain slices
these inclusions have been shown to contain FMR1 mRNA. It is theor-
ised that excess of FMR1 mRNA causes sequestration of RNA binding
proteins, forming aggregates and causing cell-wide disruption, resulting
in oxidative stress and eventual apoptosis (Tassone et al., 2000;
Hagerman and Hagerman, 2013).
Progressive motor symptoms are therefore a core feature of FXTAS,
with clinical signs of the condition only rarely manifesting before
50 years old. It is however possible that signiﬁcant neurodegeneration
is already occurring before clinical features of motor dysfunction
emerge. In order to determine whether this is indeed the case we set out
to investigate whether subtle diﬀerences in brain activation during
motor function can be elicited using functional magnetic resonance
imaging (fMRI), even in premutation carriers without a diagnosis of
FXTAS. We utilized a ﬁnger tapping task which contained both se-
quential and random ﬁnger tapping components. Compared to planned
sequential tapping, random, choice-driven tapping is known to elicit
higher levels of activation in classical motor regions and rely more upon
regions of higher cognitive functioning, such as the dorsolateral pre-
frontal cortex (Gountouna et al., 2010). To the authors' knowledge,
there have been no previous neuroimaging studies which have ex-
amined these functions in premutation carriers, although other studies
have investigated brain changes in carriers without FXTAS. A sys-
tematic review of neuroimaging studies in premutation carriers pro-
vides an overview of these ﬁndings (Brown and Stanﬁeld, 2015), in-
cluding a reduction in brainstem volume in carriers without FXTAS
(Cohen et al., 2006), signiﬁcant correlation between hippocampal vo-
lume and anxiety measures in female carriers without FXTAS (Adams
et al., 2010), signiﬁcant elevations in axial and radial diﬀusivities in
male carriers without FXTAS (Hashimoto et al., 2011) and signiﬁcantly
lower BOLD response at the right temporoparietal junction compared to
controls during a working memory task in a group of male and female
asymptomatic carriers (Kim et al., 2014). Finger-tapping studies in
other neurodegenerative disorders, such as Huntington Disease
(Bartenstein et al., 1997; Kloppel et al., 2009), Spinocerebellar Ataxia
Type 3 (Duarte et al., 2016; Cleary and Ranum, 2014) and Parkinson
Disease (Lewis et al., 2011) have demonstrated impaired functional
activity in motor regions and dysregulation of compensatory activity, in
particular during conditions with higher demand. The ﬁnger-tapping
task for this study was therefore designed to involve various levels of
cognitive and motor complexity using sequential and random tapping
conditions, with the intention of contrasting these two conditions
during the imaging analysis to isolate regions of changing activations in
response to task demands.
The primary aim of this study was therefore to determine whether,
compared to controls, diﬀerences in brain activation are apparent
during motor function in premutation carriers who do not have a di-
agnosis of FXTAS. The secondary aim was to use this cross-sectional
sample to look for preliminary evidence of progressive changes to brain
function in premutation carriers by comparing the relationship between
age and brain function in premutation carriers and controls. It was
hypothesised that diﬀerences in brain activation in motor regions, such
as the premotor cortex, supplementary motor area and the cerebellum,
would be seen between controls and premutation carriers without
FXTAS, in addition to diﬀerences in other regional involvement of
compensatory mechanisms (Lewis et al., 2011; Duarte et al., 2016;
Bartenstein et al., 1997; Minkova et al., 2015; Murta et al., 2016). Fi-
nally, we also predicted that the degree of change in brain activation in
carriers may show an association with levels of FMR1 mRNA and extent
of movement symptoms.
2. Materials and methods
2.1. Participants and recruitment
Male premutation carriers without FXTAS and a group of age-mat-
ched healthy male controls were recruited through the Fragile X
Society, UK. Invitation letters were sent to 1000 individuals of known
Fragile X families across the UK via the existing database held by the
Fragile X Society charitable association. Eligible participant age range
was between 20 and 70 years. Potential participants falling out with an
age range of 20–70 years, with a diagnosis of FXTAS or from a Fragile X
family but without a genetic diagnosis of the premutation were ex-
cluded. All participants had normal or corrected-to-normal vision. All
participants underwent genetic testing for FMR1 CGG repeat length
(Table 1). All participants gave fully informed written consent and were
screened for MRI eligibility and safety. The study was approved by
South East Scotland Research Ethics Committee, NHS Lothian.
2.2. Imaging methods
All MRI data was acquired using a 3.0 Tesla Siemens MRI scanner
using an 8 channel head coil. For the acquisition of functional images
the TR was 1560 ms, the TE (echo time) was 26 ms, the ﬂip angle was
66°, the FOV (ﬁeld of view) was 220 mm, slice thickness was 5 mm and
slice number per volume was 26. Slice order was interleaved and
bottom up in the axial orientation. Each participant also underwent a
T1-weighted magnetization prepared rapid acquisition gradient echo
(MPRAGE) sequence, in addition to fMRI sequences, for the purpose of
image preprocessing. For the MPRAGE acquisition the TR was 2300 ms,
the TE was 2.98 ms, the ﬂip angle was 9°, the FOV was 256 mm, slice
thickness was 1 mm and slice number per slab was 160. Structural and
functional images were acquired during the same scanning session.
The ﬁnger-tapping task designed and used for this study utilized a
block design and consisted of three conditions, based on Gountouna
et al., 2010. In the sequential tapping condition, participants were
asked to tap their thumbs and index ﬁngers on trigger buttons in a
predetermined sequence in time with a ﬂashing symbol. In the random
tapping condition, participants were asked to tap their thumbs and
ﬁngers on the trigger buttons in time with the ﬂashing symbol in a
random order of their choosing. The ﬁnal condition consisted of a
ﬂashing ﬁxation cross, where participants were asked to rest and watch
the screen (Fig. 1). The purpose of this ﬁxation/rest condition was to
allow a control condition minimising possible noise from visual sti-
mulus. The ﬂashing symbol appeared once every second, for a duration
of 0.5 s. Each condition block had a total duration of 30 s, including a
2 second prompt screen, and was repeated 4 times during the task. This
Table 1
Summary data of participant age, IQ, FMR1 mRNA level and CATSYS-2000 performance.
Participant summary data
Control mean Control SD Carrier mean Carrier SD
Age (years) 47.6 12.9 50.4 15.1
Verbal IQ 112.8 13.5 111.1 15.8
Non-verbal IQ 117.4 7.7 108.1 13.7
Composite IQ 116.4 9.1 110.4 14.9
FMR1 mRNA level 1.9 × 10−6 1.9 × 10−5 3.3 × 10−6 3.3 × 10−5
Tremor index 43 7.2 32.5 10.6
Co-ordination index 131.1 15.4 108.8 19.1
Balance index 171.9 15.6 173.0 13.0
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functional task was programmed using Presentation™ software, and was
visually presented to participants using goggles that ﬁt onto the scanner
head coil. All participants were given instructions to the task prior to
the scan, and were given practice time to memorise the tapping se-
quence for the sequential condition.
2.3. fMRI analysis
Statistical analysis on fMRI data was carried out using Statistical
Parametric Mapping software (SPM12) (Wellcome Department of
Clinical Neurology) using standard procedures.
The functional images from all participants were preprocessed using
the following steps: 1) images were realigned, estimated (for optimal
transformation from individual images to the reference using SPM12
default quality, separation, smoothing, num passes, interpolation,
wrapping and weighting parameters) and resliced 2) images were slice
timed, adjusting for interleaved and bottom up slice order 3) sub-
sequent images were then coregistered with the source structural image
from the T1-weighted MPRAGE anatomical scan 4) coregistered images
were segmented into grey matter, white matter and CSF outputs 5)
segmented (forward deformation) images were normalised to MNI
space and 6) ﬁnally, normalised images were smoothed with an 8 mm
full-width at half maximum (FWHM) Gaussian smoothing kernel.
Movement was controlled for by adding realignment parameters for
each participant as a multiple regressor into the ﬁrst level model. For
the ﬁrst-level analysis, the onsets and durations of the conditions were
modelled, excluding the prompt screen stimuli. The contrast of interest
here was between the sequential and random conditions, as we aimed
to focus on brain regions associated with the changes in demand for
movement cognition and planning. For the second-level analysis, an
explicit mask was derived from an average binarised image created
from the combined grey matter and white matter segmented images
from all participants and was used to exclude voxel data out-with the
brain tissue. Between group analyses were completed using a p
threshold value of p < 0.005 and signiﬁcant suprathreshold clusters
were deﬁned as FWE corrected p < 0.05. Firstly, between group ana-
lyses were performed using a two-sample t-test with age as a covariate.
A full factorial design was used for a secondary analysis, carried out
with age added into the model as a possible interacting variable.
CGG repeat analysis revealed that some individuals in the sample
were mosaic or borderline for the full mutation. To ensure this was not
causing a bias in the results, a one-way ANOVA of 3 age-matched
groups, followed by a Tukey post-hoc test was performed on extracted
voxel data from the maximum voxel of the signiﬁcantly diﬀerent be-
tween group cluster and a univariate analysis of variance was per-
formed on extracted voxel data from the age interaction signiﬁcant
cluster.
2.4. Tremor, balance and co-ordination measurements
Although no participants had frank symptoms of FXTAS, detailed
quantiﬁcation of tremor, balance and co-ordination was conducted to
examine for sub-threshold symptomatology using the CATSYS 2000 PC-
based test system. This system has previously been used in other studies
to establish that carriers without FXTAS exhibit worse co-ordination
scores and to generate estimates of age-related prevalence of tremor
and ataxia in carriers (Allen et al., 2008; Aguilar et al., 2008). Here,
index scores were obtained as standard deviations of normal human
performance, as deﬁned by the CATSYS 2000 test battery, with per-
formance indices above 1 being better than normal human performance
and indices below 1 being below normal human performance (Danish
Product Development Ltd., 1988).
2.5. Molecular measurements
DNA was isolated from blood samples for both control and carrier
participants. The assay for CGG repeat length in the FMR1 gene was
carried out using a PCR-only approach based on Triplet Repeat Primed
PCR design (AmplideX® PCR/CE FMR1 reagents).
Whole blood was collected from all participants and processed to
isolate total RNA. Total RNA was then reverse transcribed into cDNA,
using RT-PCR methodology. RT reactions were performed in 25 μl ali-
quots containing 10 μl of patient total RNA sample, 12.5 μl 2× RT
buﬀer and RT enzyme mix (Invitrogen Superscript). RT thermal cycling
conditions were as follows: 25 °C for 10 min, 50 °C for 30 min, 85 °C for
5 min and 4 °C for 15 min. 1 μl of RNase H was subsequently added to
each aliquot and the samples were incubated at 37 °C for 20 min. Each
sample was then diluted to a cDNA concentration of 6 ng/μl. These
dilutions were then used to quantify FMR1 mRNA using quantitative
PCR (qPCR). In the present investigation, the FMR1 amplicon is a
130 bp product and the following primer pair was used: forward primer
5′-AGGCAGTTGGTGCCTTTTCT-3′, starting at bp185, reverse primer
5′-TTAGTGCGCAGACTCCGAAA-3′ starting at bp314. The FMR1 primer
pair was validated (primer eﬃciency = 101.01%, R2 =−0.998) and
aliquots were prepared in triplicate for each sample, with each aliquot
containing 0.6 μl 300 nM forwards primer, 0.6 μl 300 nM reverse
primer, 10 μl SYBR Green (Qiagen), 11.8 μl H2O and 1 μl 6 ng/μl cDNA
sample. An additional control was run in triplicate on each plate with
cDNA replaced by H2O. Thermal cycling conditions for the qPCR were
as follows: 95 °C for 15 min, (94 °C for 20 s, 59 °C for 30 s and 32 °C for
30 s) ×35 cycles, then 95 °C for 1 min, 60 °C for 30 s and 90 °C for 30 s.
All FMR1 mRNA measurements were normalised to 18 sRNA mea-
surements from the samples (average primer eﬃciency = 91.28%,
R2 =−0.994), which were also ran in triplicate on the same qPCR
plate as the FMR1 mRNA probes. All samples underwent qPCR analysis
on the same plate as their age-matched counterpart. Carrier FMR1
mRNA was then additionally normalised to age-matched control.
2.6. Statistical analyses
Imaging analyses are detailed above. Further statistical analyses
were carried out in SPSS Statistics 22. A two-tailed t-test was used to
discern diﬀerences between the premutation and control groups for the
tremor, balance and coordination measurements, in addition to the
FMR1 mRNA data. Simple linear regressions were also performed on
Fig. 1. Finger-tapping task behavioural conditions and block design.
S.S.G. Brown et al. NeuroImage: Clinical 17 (2018) 761–767
763
extracted raw voxel values from signiﬁcant clusters against the move-
ment and molecular variables. All signiﬁcance levels were assumed at
p < 0.05.
3. Results
3.1. Participants
Male premutation carriers without FXTAS (n= 17, mean age
50.4 years, SD = 15.1) and a group of age-matched healthy male con-
trols (n= 17, mean age 47.6 years, SD = 12.9) were recruited for this
study. CGG repeat testing revealed that 12 carriers were within the
premutation range, 1 carrier was in the intermediate range, 3 carriers
were mosaic for repeat size and one carrier was borderline for the full
mutation. All control subjects were within the normal CGG repeat
length range (Supplementary Table 1). All participants were right
handed, apart from one control and two carriers, and all participants
had an IQ> 80, as measured by the KBIT Second Edition Intelligence
Test (Pearson). Participant summary data is shown in Table 1.
3.2. Between group imaging results
Between group full factorial analysis revealed that the premutation
group had a signiﬁcantly lower cluster of BOLD response
(FWEcorr < 0.001, T= 5.59) at the bilateral lobules VI of the cere-
bellum, left lobule V and the left hippocampus (subiculum) compared
to controls. The maximum of the cluster was located at
[−12,−36,−12] (Fig. 2a).
As analysis of FMR1 CGG repeat length revealed a number of car-
riers in the sample to be mosaic or borderline for the full mutation, a
third group was created of mosaic and borderline carriers to examine
whether they were skewing the imaging results. The groups for the
ANOVA analysis were deﬁned as the following: control (n= 17), pre-
mutation (n= 13) and mosaic/borderline carriers (n= 4). A statisti-
cally signiﬁcant between group diﬀerence in BOLD response at the
signiﬁcant cluster maximum voxel [−12,−36,−12] was identiﬁed by
one-way ANOVA (F(2,31) = 14.249, p < 0.001). A Tukey post-hoc
test revealed that BOLD response for this cluster was signiﬁcantly dif-
ferent in controls compared to carriers (p < 0.001) and controls
compared to mosiac/borderline carriers (p= 0.026), but not sig-
niﬁcantly diﬀerent between carriers and mosaic/borderline carriers
(p= 0.784). Representative group means are presented in Fig. 2b.
3.3. Age-related between group imaging results
In the analysis of age related diﬀerences, a signiﬁcant group × age
interaction was seen in a cluster centred in left Brodmann Area (BA) 17
in the primary visual cortex, which extended to the left hippocampus
(cornu ammonis), the left inferior parietal cortex and the left temporal
lobe (FWEcorr < 0.001, T= 5.22). The maximum of the cluster is lo-
cated at [−26,2,36] (Fig. 3a). Plotting extracted values from this
cluster indicated there was a negative relationship between age and
activation in this cluster in the premutation group, while the relation-
ship was positive in the control group. Within group regression analysis
revealed both of these relationships to be signiﬁcant (Table 2).
A univariate analysis of variance was also carried out on this sig-
niﬁcant cluster to ensure anomalous CGG repeat lengths were not
causing a bias in the imaging results. The groups for the univariate
analysis of variance analysis were deﬁned as the following: control
(n= 17), premutation (n= 13) and mosaic/borderline carriers
(n= 4). A statistically signiﬁcant group × age interaction was identi-
ﬁed in BOLD response at the signiﬁcant cluster maximum voxel
[−26,2,36] (p < 0.001), and plotting of group × age extracted voxel
data demonstrates that both the premutation and the mosaic/border-
line group diﬀer signiﬁcantly to controls but not to each other (Fig. 3b).
3.4. Tremor, balance and co-ordination results
Although none of this population of carriers had a diagnosis of
FXTAS, the CATSYS-2000 system identiﬁed carriers as having sig-
niﬁcantly worse tremor and co-ordination scores than controls
(p= 0.002, p= 0.001), and balance showed no diﬀerence between the
groups (p= 0.931). Both populations had mean performance indices of
better than normal human performance on the co-ordination and bal-
ance measurements and below normal human performance on the
tremor measurement (Table 1).
3.5. FMR1 mRNA analysis
Quantitative PCR analysis revealed that the premutation carriers did
not have signiﬁcantly higher levels of FMR1 mRNA relative to 18 sRNA
when measured from peripheral blood samples (p= 0.3223) (Fig. 4a).
However, normalization of carrier FMR1 mRNA relative to 18 sRNA to
age-matched control data showed that some carriers have up to a 7-fold
increase in FMR1 mRNA when compared directly to an age-matched
control (Fig. 4b). To examine again whether the borderline or mosaic
carriers were causing anomalies in the data, these individuals were
again examined separately from the other premutation carriers.
Fig. 2. Between group imaging results a) Premutation group signiﬁcantly less activated (FWEcorr < 0.001, T= 5.59) at the bilateral lobules VI of the cerebellum, left lobule V and the
left hippocampus (subiculum) in the sequential> random condition contrast. Cluster co-ordinate of maximum voxel:−12,−36,−12, k= 2040, normalised voxel size: 2 mm3 b) Mean
extracted voxel response by grouping at [−12,−36,−12].
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Borderline or mosaic carrier FMR1 mRNA level relative to 18 sRNA and
normalised to age-matched control show no signiﬁcant diﬀerences
compared to other carriers.
3.6. Linear regression analyses
Simple linear regression analyses were carried out on the imaging,
clinical and FMR1 mRNA variables of interest (Supplementary Fig. 1,
Supplementary Table 2). Extracted raw voxel data from the cluster
global maxima originating from both the between group analysis and
the group × age interaction analysis were regressed against measures
of tremor, co-ordination, balance and FMR1 mRNA levels. No sig-
niﬁcant associations were identiﬁed in either carriers or controls
(Supplementary Fig. 1a and 1b).
4. Discussion
This is the ﬁrst study to examine brain activation during a motor
task in FMR1 premutation carriers who do not have frank symptoms of
FXTAS. Consistent with the primary hypothesis, despite the lack of
clinical symptomatology, diﬀerences between carriers and controls
were identiﬁed when contrasting random and sequential ﬁnger-tapping
conditions in this fMRI task in the bilateral lobules VI of the cerebellum,
left lobule V and the left hippocampus (subiculum).
The cerebellum is a brain region which is strongly associated with
movement initiation and processing, as well as being a site of degen-
eration in FXTAS (Berry-Kravis et al., 2007). We now show a pre-
symptomatic functional BOLD response alteration in the cerebellum,
extending into the hippocampus, during a ﬁnger-tapping task in a
premutation population. Pertinently, recent evidence shows that car-
riers without FXTAS display a faster age-related decrease in cerebellar
volume than controls. Signiﬁcantly larger ventricles and signiﬁcant
group × age interactions in the brainstem and whole brain volumes
Fig. 3. Age-related between group imaging results a) Signiﬁcant group × age interaction (FWEcorr < 0.001, T= 5.22) at the left BA17, left hippocampus (CA), left inferior parietal
cortex and left temporal in the sequential > random condition contrast. Cluster co-ordinate of maximum voxel: −26,2,36, k= 2105, normalised voxel size: 2 mm3 b) Fit linear
regression lines comparing positive control BOLD response and age relationship compared to negative premutation carrier BOLD response and age relationship at maximum cluster voxel
[−26,2,36].
Table 2
Statistical results of within group regression analyses between participant age and BOLD
activation at [−26,2,36].
Within group age/BOLD activation regression analyses
Group DV IV β Standard
error
Adjusted R2 p Value
Control Age BOLD
response at
[−26,2,36]
0.763 0.001 0.554 < 0.001
Premutation Age BOLD
response at
[−26,2,36]
−0.595 0.001 0.312 0.012
Fig. 4. FMR1 mRNA quantiﬁcation. a) FMR1 mRNA amount relative to 18 sRNA control for carrier and control groups b) Carrier FMR1 mRNA amount relative to 18 sRNA normalised to
age-matched control levels and control FMR1 mRNA amount relative to 18 sRNA normalised to control average.
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were also identiﬁed in carriers without FXTAS (Wang et al., 2017).
Sensorimotor mapping of the cerebellum labels lobule V of the cere-
bellum as primarily related to movements of the hand and ﬁnger-tap-
ping tasks have previously been found to reliably activate cerebellar
lobule V, with more cognitively demanding tasks also recruiting lobule
VI (Stoodley et al., 2012; Grodd et al., 2001). Our ﬁnding of sig-
niﬁcantly lower activation at lobule VI of the cerebellum may well
reﬂect deﬁcits in recruitment during higher levels of demand during the
task, in addition to a lower level of basic sensorimotor processing at
lobule V. The hippocampus is not routinely cited as being signiﬁcantly
activated during within group analyses of fMRI motor tasks, however
the extension of the signiﬁcant between group cluster to the hippo-
campal subiculum may also indicate a deﬁcit in more diﬀuse recruit-
ment in response to a change in task demand (De Guio et al., 2012;
Berns et al., 1999). This type of evidence of signiﬁcant diﬀerences be-
tween carriers without FXTAS and controls during a motor task is
suggestive of neurological vulnerability to disease prior to onset.
A signiﬁcant group × age interaction was also identiﬁed that re-
vealed that, compared to controls, carriers showed a signiﬁcantly more
negative association between age and activation in the left BA17, left
hippocampus (cornu ammonis), left inferior parietal cortex and left
temporal lobe. Within group regression analysis of this data revealed
that both the positive age-related correlation in the control group and
the negative age-related correlation in the premutation group were
signiﬁcant. In normal elderly populations, ﬁnger-tapping has been seen
to elicit over-recruitment of the occipito-temporo-parietal regions,
suggesting an increased level of visual or mental strategizing (Zapparoli
et al., 2013). This idea of compensatory activity is reﬂected in our re-
gression analysis, with activation in the temporo-parietal cluster iden-
tiﬁed in this analysis showing a positive linear relationship with in-
creasing age in the control population. However, this cluster shows
signiﬁcant deactivation in relation to age in the premutation group,
suggesting that there is degeneration aﬀecting the functional compen-
satory response to changes in movement demands.
In addition to imaging data, the present study utilized clinical
measurements of tremor, co-ordination, balance and FMR1 mRNA to
further characterise the participant sample. Performance on the tremor
and co-ordination measurements was signiﬁcantly worse in carriers,
suggesting subtle non-clinical symptoms. Balance however was not
signiﬁcantly diﬀerent than in controls, and this may be explained by
balance being aﬀected later on during FXTAS progression, as falls are
not often reported in early disease stages, meaning that balance
symptomatology is not present in this asymptomatic or pre-clinical
sample. None of these variables exhibited an association with the raw
voxel data extracted from the between group analysis at the cluster at
the bilateral lobules VI of the cerebellum, left lobule V and the left
hippocampus (subiculum). It is possible in this case that a relatively
small sample size for this study may have led to these results not
reaching signiﬁcance. Additionally, in the absence of overt FXTAS, it
may be that symptomatology and functional brain changes are not yet
developed enough to display a signiﬁcant relationship, and a cross-
sectional asymptomatic sample in this case may have led to a bias to-
wards carriers with a lower FXTAS risk, especially in the older parti-
cipants. Tremor, co-ordination and balance as measured by the
CATSYS-2000 system also did not prove to be signiﬁcantly associated
with raw voxel data extracted from the age-related signiﬁcant cluster at
the left BA17, left hippocampus (cornu ammonis), left inferior parietal
cortex and left temporal lobe. This may be due to the likelihood of this
predominantly limbic cluster being more relevant to compensatory
activity and motor imagery, instead of overt motor processing and as-
sociated deﬁcits, in addition to the aforementioned limitations re-
garding power to detect a small eﬀect size and the present study's cross-
sectional design.
Measurements of FMR1 mRNA from peripheral blood samples did
not show any relationship with signiﬁcant diﬀerences in BOLD re-
sponse, in either the between group or age-related analysis. FMR1
mRNA levels are thought to be one of the primary molecular driving
forces of neurodegenerative processes in FXTAS, and it is therefore
somewhat surprising that FMR1 mRNA amount is not related to these
functional imaging changes. Our ﬁndings contrast with previous studies
that support the hypothesis that early signs of brain changes associated
with FXTAS correlate with changes in mRNA levels or metabolism
(Cohen et al., 2006; Adams et al., 2007). These studies found that
hippocampal volume and IQ scores were correlated with FMR1 mRNA
in premutation carriers. However, our ﬁndings are in agreement with
other studies that found mRNA measurements from peripheral blood
may be only weakly correlated with brain expression (Tassone et al.,
2007; Cohen et al., 2006; Leehey et al., 2008). It is possible however
that variation in asymptomatic premutation carrier populations in
terms of future FXTAS penetrance may be a contributing factor to the
discrepancies in the ﬁndings into FMR1 mRNA levels in carriers. To
elucidate this further, work in the ﬁeld should attempt to strive towards
methodology that can more directly identify molecular changes in the
brain in vivo or post mortem.
Previous functional MRI research studies have also observed func-
tional abnormalities in premutation carriers without FXTAS. During
associative memory recall tasks, increases in activation at the parietal
cortex is suggestive of compensatory mechanisms within premutation
carrier groups, given that performance in the task was not signiﬁcantly
diﬀerent to control subjects (Koldewyn et al., 2008). This type of neural
compensation may be important in the carrier phenotype, allowing
individuals to counteract processing deﬁciencies and appear outwardly
asymptomatic. Findings of reduced activation in the limbic system of
carriers is also further evidence of the higher incidences of social and
psychiatric problems in carrier populations, and may indeed be linked
to structural ﬁndings, such as volume loss at the amygdala (Hessl et al.,
2011). Additionally, during a scanner task that involved the presenta-
tion of neutral faces to participants, premutation carriers were observed
to respond to this type of stimuli with greater overall brain activation,
which again may be reﬂective of social diﬃculties and neuropsycho-
logical abnormalities (Hessl et al., 2007). On the whole, fMRI in FMR1
premutation carriers has shown a reduction in the BOLD signal at
multiple diﬀerent brain regions in response to varied stimuli. However,
the literature is not without conﬂicting results, and some research
groups have demonstrated no signiﬁcant diﬀerences in comparison to
control groups during functional testing (Wang et al., 2012). This ab-
sence of diﬀerences between groups may arise for many diﬀerent rea-
sons, one such important reason being that the heterogeneity of the
premutation phenotype and percentage of FXTAS penetrance may cause
studied groups of carriers to vary considerably. The present study
however is consistent with the existence of altered BOLD response in
carriers who do not show clinical signs of FXTAS.
Overall, we ﬁnd novel results pertaining to motor function and re-
sponse to variation in task demand using functional neuroimaging in
Fragile X premutation carriers. Our results show brain changes in car-
riers in the cerebellar and limbic regions which are likely to reﬂect
functional impairment of compensatory mechanisms and response to
increased task demand. These changes pre-exist the diagnosis of FXTAS
and are most marked in older carriers, suggesting that they may be
indicative of FXTAS vulnerability. Future longitudinal studies are re-
quired to conﬁrm this.
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